Evidence map›Paper›PMID 35885648›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care.

Maxim Lebedev, Aaron B Benjamin, Kent J Koster, Kathryn E Broyles, Sathish Kumar, Joseph M Jilka, Jeffrey D Cirillo

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Expert review of respiratory medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maxim LebedevDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.ORCID 0000-0003-3188-1595
Aaron B BenjaminDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.ORCID 0000-0003-4387-2434
Kent J KosterDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.
Kathryn E BroylesDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.
Sathish KumarDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.
Joseph M JilkaPulmonescence Diagnostics, Inc., Temple, TX 76504, USA.
Jeffrey D CirilloDepartment of Microbial Pathogenesis and Immunology, Texas A&M School of Medicine, Bryan, TX 77807, USA.ORCID 0000-0003-3058-2702
Texas A&M Health Science Center · US

Funding

Application of Imaging to Development of Tuberculosis InterventionsR01AI104960 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI CIRILLO, JEFFREY D. · 2014 to 2018
$1.9M
Design of hetero-multivalent targeted liposome for combating intracellular Mycobacterium tuberculosisR21AI149383 · NIAID · TEXAS ENGINEERING EXPERIMENT STATION · PI CIRILLO, JEFFREY D., WU, HUNG-JEN · 2020 to 2021
$416k
Development of a Rapid Low-Cost Fecal-based TB Diagnostic for ChildrenR41AI155206 · NIAID · PULMONESCENCE DIAGNOSTICS, INC. · PI CIRILLO, JEFFREY D. · 2020 to 2020
$244k
NIAID NIH HHS R01 AI104960NIAID NIH HHS R21 AI149383NIAID NIH HHS R41 AI155206NIH HHS AI104960NIH HHS AI149383NIH HHS AI155206
6 · The paper itself

Abstract

Tuberculosis is one of the most frequent causes of death in humans worldwide. One of the primary reasons tuberculosis remains a public health threat is that diagnosis can take weeks to months, is often not very sensitive and cannot be accomplished in many remote environments. A rapid, sensitive and inexpensive point-of-care (POC) diagnostic would have a major impact on tuberculosis eradication efforts. The tuberculosis diagnostic system REFtb is based on specific detection of the constitutively expressed β-lactamase (BlaC) in Mycobacterium tuberculosis using a custom fluorogenic substrate designated as CDG-3. REFtb has potential as a diagnostic for tuberculosis that could be very inexpensive (<USD 2.00/test), used at the POC and could provide definitive diagnosis within 10 min. However, the reagents for REFtb are currently in liquid form, making them more susceptible to degradation and difficult to transport. We evaluated the improvement in the stability of REFtb reagents by lyophilization under a variety of conditions through their effects on the performance of REFtb. We found that lyophilization of REFtb components produces an easily reconstituted powder that displays similar performance to the liquid system and that lactose represents one of the most promising excipients for use in a final POC REFtb diagnostic system. These studies provide the foundation for the production of a stable POC REFtb system that could be easily distributed worldwide with minimal or no requirement for refrigeration.

Indexed as

beta lactamaseBlaCBlue Sepharosediagnosticsexcipientlactoselyophilizationmannitoltuberculosis

Identifiers

PMID35885648
PMCPMC9324015
OpenAlexW4285799786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.